Natalie R. Budilovsky-Kelley
YOU?
Author Swipe
View article: Interpreting extended-release buprenorphine data: The importance of specifying formulations and accurately representing prior evidence
Interpreting extended-release buprenorphine data: The importance of specifying formulations and accurately representing prior evidence Open
View article: Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial Open
Objectives: CAM2038 weekly and monthly extended-release buprenorphine (BPN) formulations are effective for treating opioid use disorder (OUD). Little is known about the effect of dose on patient outcomes, particularly under blinded and fle…
View article: Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use
Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use Open
Importance Fentanyl has exacerbated the opioid use disorder (OUD) and opioid overdose epidemic. Data on the effectiveness of medications for OUD among patients using fentanyl are limited. Objective To assess the effectiveness of sublingual…
View article: 236 Buprenorphine Treatment Persistence and Healthcare Expenditures: A Retrospective Claims Study
236 Buprenorphine Treatment Persistence and Healthcare Expenditures: A Retrospective Claims Study Open